Last updated: November 5, 2026
Darolutamide, marketed as Nubeqa by Bayer and Orion, is one of the fastest-growing oral androgen-receptor inhibitors in prostate cancer. Global sales reached approximately €1.0 billion in 2023, up from about €669 million in 2022 and €328 million in 2021. Growth is being driven by expansion from nonmetastatic castration-resistant prostate cancer into metastatic hormone-sensitive prostate cancer, broader use with androgen-deprivation therapy and docetaxel, and increasing physician adoption of an androgen-receptor inhibitor with limited blood-brain-barrier penetration.
Bayer has identified Nubeqa as a strategic growth product with peak sales potential above €3 billion. The principal commercial risks are competition from enzalutamide and apalutamide, price pressure from generic abiraterone, future generic or authorized-generic challenges, and clinical competition from combination regimens that avoid chemotherapy.
What is darolutamide and how does Nubeqa work?
Darolutamide is a nonsteroidal androgen-receptor inhibitor. It binds the androgen receptor and inhibits receptor signaling, nuclear translocation, and transcription of androgen-responsive genes. The drug is administered orally and is generally used with androgen-deprivation therapy.
Its principal commercial distinction is relatively low penetration across the blood-brain barrier compared with some earlier androgen-receptor inhibitors. That characteristic is relevant because central nervous system adverse effects, including fatigue, falls, cognitive effects, and seizure concerns, influence treatment selection in older prostate-cancer patients.
Nubeqa is available as 300 mg tablets. The recommended dose is 600 mg twice daily with food, for a total daily dose of 1,200 mg.
Which prostate-cancer indications are approved?
| Market |
Indication |
Key regulatory milestone |
| United States |
Nonmetastatic castration-resistant prostate cancer |
FDA approval, July 2019 |
| United States |
Metastatic hormone-sensitive prostate cancer with docetaxel and ADT |
FDA approval, August 2022 |
| United States |
Broader mHSPC use with ADT and docetaxel |
FDA supplemental approval, June 2024 |
| European Union |
nmCRPC and later mHSPC combination use |
European Commission approvals based on ARAMIS and ARASENS |
| Japan and other markets |
Prostate-cancer indications vary by jurisdiction |
Local approvals and label expansions |
The regulatory trajectory matters commercially. The original nmCRPC indication created the initial market. The ARASENS-based mHSPC indication increased the addressable population by moving darolutamide into earlier-line treatment and combination therapy.
How large is the darolutamide market?
The global market for androgen-receptor pathway inhibitors is led by established products such as enzalutamide and apalutamide, but darolutamide has gained share rapidly since launch.
What are Nubeqa’s reported sales?
| Fiscal year |
Bayer Nubeqa sales |
Approximate year-over-year growth |
| 2021 |
€328 million |
|
| 2022 |
€669 million |
104% |
| 2023 |
€1.0 billion |
Approximately 50% |
| Bayer long-term target |
More than €3 billion peak sales |
Company target |
Source: Bayer annual reports and financial disclosures.
Sales growth reflects both volume and label expansion. The 2022 United States approval in mHSPC was particularly important because mHSPC treatment is initiated earlier than nmCRPC therapy. Earlier treatment creates a larger pool of eligible patients, although treatment duration and competition are also greater.
Bayer reports pharmaceutical sales by product, while Orion reports its economic interest under the companies’ collaboration structure. Reported Bayer sales therefore do not represent Bayer’s full economic profit after royalties, marketing costs, development spending, manufacturing expenses, and other product-related deductions.
Which regions are driving growth?
The United States is the principal value market because of high oncology pricing and strong use of oral androgen-receptor inhibitors. Europe contributes substantial volume but generally has slower reimbursement uptake, country-specific health technology assessments, and more pronounced price controls.
Japan, China, and other Asian markets provide additional growth opportunities. Access timing is uneven, and reimbursement decisions often depend on local clinical guidelines, chemotherapy use, and whether the indication is treated as metastatic hormone-sensitive disease or castration-resistant disease.
What clinical evidence supports darolutamide adoption?
How did the ARAMIS trial affect the nmCRPC market?
The phase 3 ARAMIS trial evaluated darolutamide plus androgen-deprivation therapy against placebo plus androgen-deprivation therapy in men with nonmetastatic castration-resistant prostate cancer. Darolutamide significantly improved metastasis-free survival and later demonstrated an overall-survival benefit.
The ARAMIS data supported the initial FDA approval and established Nubeqa as a treatment for patients with rising prostate-specific antigen levels despite castrate testosterone levels and no detectable distant metastases.
The nmCRPC segment is strategically valuable because it has a relatively defined treatment population and established monitoring pathway. Its limitation is that the patient pool is smaller than the metastatic hormone-sensitive population.
How did ARASENS expand the commercial opportunity?
The phase 3 ARASENS trial evaluated darolutamide or placebo, each given with docetaxel and androgen-deprivation therapy, in metastatic hormone-sensitive prostate cancer. Darolutamide improved overall survival and reduced the risk of disease progression or death.
ARASENS changed Nubeqa’s commercial positioning in three ways:
- It moved darolutamide into an earlier disease setting.
- It created a triplet-regimen commercial opportunity with docetaxel and ADT.
- It gave Bayer a differentiated evidence base against androgen-receptor inhibitors used with ADT alone.
The chemotherapy requirement initially limited the label’s breadth. The commercial opportunity is larger if darolutamide can be used effectively with ADT without docetaxel. Bayer and Orion have pursued this question through the ARANOTE program.
What is the status of the ARANOTE evidence?
ARANOTE evaluates darolutamide plus androgen-deprivation therapy without docetaxel in metastatic hormone-sensitive prostate cancer. Positive results would support a broader and more convenient regimen for patients who are not candidates for chemotherapy or whose physicians prefer a doublet approach.
A successful non-docetaxel label would increase the addressable market but would also place Nubeqa into more direct competition with enzalutamide, apalutamide, abiraterone, and emerging prostate-cancer combinations.
How does darolutamide compare with competing prostate-cancer drugs?
| Product |
Active ingredient |
Principal companies |
Key commercial position |
| Nubeqa |
Darolutamide |
Bayer, Orion |
Low CNS penetration; nmCRPC and mHSPC; triplet evidence |
| Xtandi |
Enzalutamide |
Pfizer, Astellas |
Broad prostate-cancer use; established global franchise |
| Erleada |
Apalutamide |
Johnson & Johnson |
nmCRPC and mHSPC; strong early-line positioning |
| Zytiga |
Abiraterone acetate |
Johnson & Johnson and generics |
Effective, lower-cost generic competition |
| Orgovyx |
Relugolix |
Sumitomo Pharma, Pfizer in certain arrangements |
Oral GnRH antagonist; androgen-deprivation therapy rather than AR inhibition |
| Pluvicto |
Lutetium-177 vipivotide tetraxetan |
Novartis |
Radioligand therapy for later-line PSMA-positive disease |
How strong is darolutamide’s clinical differentiation?
Darolutamide’s strongest differentiators are its pharmacologic profile and combination evidence. Its lower central nervous system penetration supports use in older patients who may be vulnerable to fatigue, falls, cognitive effects, or drug-drug interactions.
Its principal disadvantage is treatment cost relative to generic abiraterone. Darolutamide also competes against oral agents with longer commercial histories and broader physician familiarity.
Enzalutamide has the largest historical commercial footprint among oral androgen-receptor inhibitors. Apalutamide competes most directly in earlier-line disease. Abiraterone remains a major economic competitor because generic versions substantially reduce treatment cost, even though abiraterone requires prednisone and has different safety and monitoring considerations.
What patents protect darolutamide and Nubeqa?
The core United States patent estate is based on compound and androgen-receptor-modulator patent families developed by Orion and Bayer. A principal U.S. patent associated with darolutamide is U.S. Patent No. 9,266,856, which has been reported with an expiration date in November 2030, before any applicable patent-term extension.
What is the Orange Book status of Nubeqa?
Nubeqa is an FDA-approved small-molecule drug listed in the FDA Orange Book. Its listed patent protection includes compound and drug-product-related claims. Orange Book patents are relevant because an abbreviated new drug application applicant must address listed patents through a Paragraph IV certification or wait until the relevant patent protections expire.
| Protection category |
Commercial relevance |
| Active pharmaceutical ingredient and compound claims |
Protect the darolutamide molecule and related chemical structures |
| Drug-product claims |
Cover the marketed tablet and pharmaceutical composition |
| Method-of-use claims |
Cover approved prostate-cancer treatment methods |
| Regulatory exclusivity |
Prevents certain abbreviated applications during the applicable FDA exclusivity period |
| Patent-term extension |
May extend a qualifying patent beyond its ordinary expiration date |
Patent protection should be analyzed separately from regulatory exclusivity. FDA exclusivity can restrict approval of competing applications even when patent issues are disputed. Patent litigation can also delay approval or launch beyond the earliest technically available date.
When does darolutamide lose exclusivity?
The core U.S. patent estate is expected to provide protection into approximately 2030, subject to the specific patent, patent-term adjustment, pediatric exclusivity, patent-term extension, litigation outcomes, and settlement terms.
A generic applicant could seek approval before patent expiry through a Paragraph IV certification. The likely commercial entry date would depend on whether the applicant wins litigation, reaches a settlement with Bayer and Orion, or launches at risk.
European and other international exclusivity dates differ because patent prosecution, supplementary protection certificates, regulatory exclusivity, and national litigation outcomes vary by country.
Are generic companies challenging Nubeqa?
Publicly visible generic competition has not yet produced a broad Nubeqa launch in the United States. The key future pathway is an ANDA with Paragraph IV certification against Orange Book-listed patents.
A first successful Paragraph IV filer may obtain 180 days of generic exclusivity under the Hatch-Waxman framework, depending on the statutory status of the application and forfeiture rules. That period could create a temporary duopoly between the authorized product and first generic before additional generic entrants arrive.
What generic launch scenarios exist?
| Scenario |
Likely market effect |
| No challenge before core patent expiry |
Nubeqa retains branded pricing through the protected period |
| Early Paragraph IV settlement |
Entry may occur before patent expiry under confidential or public settlement terms |
| Successful Paragraph IV litigation |
Generic entry could occur before the listed patent expiry |
| At-risk launch |
Generic sales could begin before final patent resolution, creating substantial damages exposure |
| Post-expiry multi-generic entry |
Rapid price erosion and loss of branded volume are likely |
Generic substitution for Nubeqa could be slower than substitution for simpler, low-cost oral drugs because prostate-cancer treatment is managed by specialists and payers often apply formulary controls. Price erosion would still be material if several ANDA products enter simultaneously.
What is the regulatory exclusivity position for darolutamide?
Darolutamide received FDA approval in 2019. The regulatory exclusivity period associated with the original approval has expired, leaving patent protection as the principal U.S. barrier to generic entry.
The 2022 and 2024 label expansions improve the product’s clinical and commercial position but do not necessarily create a new period of broad market exclusivity for the active ingredient. Supplemental approvals can support specific method-of-use protection where valid patents are listed, but they do not reset the entire product’s patent or exclusivity clock.
FDA approval of Nubeqa is distinct from its Orange Book patent status. FDA reviews safety, efficacy, quality, and labeling. The courts determine patent infringement and validity in Paragraph IV litigation.
What licensing deals support darolutamide commercialization?
Darolutamide originated from Orion’s androgen-receptor research program. Bayer and Orion entered into a global collaboration covering development and commercialization. Bayer has commercialized Nubeqa broadly outside territories retained by Orion, while Orion has maintained a role in the collaboration and Nordic commercialization structure.
The partnership reduces Bayer’s discovery risk and gives Orion access to Bayer’s global oncology infrastructure. It also divides economics between the companies through royalties, milestones, commercial rights, and regional arrangements. The precise financial terms are not fully disclosed in public company reporting.
The collaboration is commercially important because Nubeqa requires global regulatory execution, large oncology trials, manufacturing scale, and payer negotiations. Bayer supplies the scale; Orion retains participation in the product’s economic upside.
What manufacturing and intellectual-property barriers affect Nubeqa?
Darolutamide is a chemically synthesized small molecule, so it does not have the cell-line, biosimilar, or cold-chain complexity associated with biologic drugs. A generic manufacturer would not face biosimilar approval risk. It would file an ANDA demonstrating pharmaceutical equivalence and bioequivalence.
The principal barriers are:
- Validity and infringement risk involving compound, formulation, and use patents.
- Development of a bioequivalent tablet with matching dissolution and exposure.
- Control of impurities and solid-state properties.
- Reliable supply of active pharmaceutical ingredient and intermediates.
- Regulatory approval in multiple jurisdictions.
- Commercial access to oncology distribution channels.
- Payer substitution and specialist prescribing behavior.
There is no conventional biosimilar pathway for darolutamide because it is a small-molecule drug. Competitive risk is therefore generic rather than biosimilar risk.
What patent litigation affects darolutamide?
No broad, high-impact U.S. Nubeqa Paragraph IV litigation wave had materially disrupted the product’s commercial trajectory through the latest reported sales period. The primary future litigation risk is ANDA litigation as the core patent term approaches expiration.
Potential disputes could involve:
- Validity of the compound patent.
- Infringement by a generic darolutamide tablet.
- Scope of formulation claims.
- Use claims covering treatment of nmCRPC or mHSPC.
- Patent-term calculations.
- Settlement restrictions under antitrust scrutiny.
Any settlement could materially alter the effective loss-of-exclusivity date. A settlement allowing an authorized generic or licensed generic launch would produce a different revenue curve from a full patent-term defense.
What is the financial trajectory for Bayer and Orion?
Nubeqa is becoming one of Bayer’s most important growth products as the company manages declining or mature franchises in other therapeutic areas.
Bayer’s revenue exposure
At approximately €1 billion in 2023 sales, Nubeqa represented a meaningful share of Bayer’s pharmaceutical growth portfolio. The product’s revenue trajectory is supported by:
- Expansion into mHSPC.
- Longer treatment duration in earlier disease.
- Combination use with ADT and docetaxel.
- Potential adoption without docetaxel.
- Geographic label expansion.
- Continued penetration in nmCRPC.
The major downside risks are slower-than-expected uptake of combination therapy, reimbursement restrictions, physician preference for enzalutamide or apalutamide, generic abiraterone price competition, and earlier-than-expected generic entry.
How does Nubeqa compare with Bayer’s other growth products?
| Product |
Therapeutic area |
Financial role |
| Nubeqa |
Prostate cancer |
Major oncology growth driver |
| Kerendia |
Chronic kidney disease and type 2 diabetes |
Cardiovascular and renal growth product |
| Verquvo |
Heart failure |
Earlier-stage commercial product |
| Xofigo |
Prostate cancer radiopharmaceutical |
Mature and more specialized asset |
Nubeqa’s growth profile is stronger than that of a mature oncology product because its addressable population is expanding through label progression. The product also benefits from oral administration and a large prostate-cancer treatment market.
What generic entry risks exist for Nubeqa?
The main risk window is the late 2020s and early 2030s. The revenue impact will depend on the number of approved generics, the timing of first entry, formulary substitution, and whether Bayer launches or authorizes an authorized generic.
A typical erosion pattern could include a sharp reduction in net price after the first generic, followed by a larger decline in branded volume once multiple manufacturers enter. Oncology products can retain some branded demand because physicians may continue prescribing the originator, but payer incentives generally favor lower-cost alternatives.
Nubeqa’s high revenue base increases the financial importance of even a one-year difference in generic entry. If sales approach Bayer’s stated peak target before loss of exclusivity, the product could become a multibillion-euro asset exposed to substantial patent-cliff risk.
Key Takeaways
- Darolutamide is marketed as Nubeqa by Bayer and Orion.
- Bayer sales increased from approximately €328 million in 2021 to €1.0 billion in 2023.
- Growth is driven by expansion from nmCRPC into mHSPC and combination treatment.
- Bayer has identified peak sales potential above €3 billion.
- The principal competitors are enzalutamide, apalutamide, generic abiraterone, and emerging prostate-cancer combination therapies.
- The core U.S. patent estate is expected to protect the product into approximately 2030, subject to patent-specific adjustments and litigation.
- Nubeqa is a small molecule, so future competition will come through generic ANDAs rather than biosimilar applications.
- The main commercial catalysts are broader mHSPC use, ARANOTE results, additional international reimbursement, and continued specialist adoption.
- The main financial risk is Paragraph IV litigation or settlement-driven generic entry before the core patent expiry period.
FAQs
Is darolutamide a biologic drug?
No. Darolutamide is a chemically synthesized small-molecule androgen-receptor inhibitor. Generic manufacturers would use the ANDA pathway rather than the biosimilar pathway.
Is Nubeqa more effective than Xtandi?
Clinical trials have not established a universal head-to-head superiority claim between darolutamide and enzalutamide. Darolutamide’s differentiation is based on its clinical evidence, pharmacologic profile, and lower central nervous system penetration.
Does Nubeqa require chemotherapy?
Nubeqa’s ARASENS-based mHSPC regimen includes docetaxel and androgen-deprivation therapy. Ongoing and subsequent evidence evaluating darolutamide with ADT without docetaxel is important because a non-chemotherapy regimen could broaden use.
Who owns the Nubeqa patent?
The darolutamide program was developed through Orion and Bayer’s collaboration. Patent ownership and commercial rights vary by patent family and territory, while Bayer commercializes Nubeqa globally across most markets.
What happens to Nubeqa sales after generic entry?
Sales would likely decline through lower net pricing, payer substitution, and reduced branded volume. The pace of erosion would depend on the number of entrants, the timing of the first generic, patent settlements, and whether Bayer uses an authorized-generic strategy.
References
-
Bayer AG. (2022). Annual report 2022. Bayer AG.
-
Bayer AG. (2023). Annual report 2023. Bayer AG.
-
Bayer AG. (2024). Annual report and fourth-quarter results materials. Bayer AG.
-
Food and Drug Administration. (2019). FDA approves darolutamide for non-metastatic castration-resistant prostate cancer. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2022). FDA approves darolutamide with chemotherapy for metastatic hormone-sensitive prostate cancer. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Nubeqa prescribing information. U.S. Department of Health and Human Services.
-
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., et al. (2019). Darolutamide in nonmetastatic, castration-resistant prostate cancer. New England Journal of Medicine, 380(13), 1235-1246.
-
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., et al. (2022). Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. New England Journal of Medicine, 386(12), 1132-1142.
-
U.S. Patent No. 9,266,856. (2016). Androgen receptor modulators. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
